Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
June 17, 2008 08:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill. and BRISTOL, Tenn., June 17, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today announced positive top-line results from...
Acura Pharmaceuticals, Inc. Announces Notice of Allowance for Second Aversion Technology Patent
June 03, 2008 16:05 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., June 3, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced receipt from the United States Patent and Trademark Office of a Notice of Allowance for a...
Acura Pharmaceuticals, Inc. Announces Active IND for Second Opioid Analgesic Product Candidate Using Aversion Technology
June 02, 2008 16:05 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., June 2, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that clinical evaluation is now allowed under an active Investigational New Drug application...
King Pharmaceuticals Exercises Option to License Third Opioid Product Utilizing Acura's AVERSION Technology
May 27, 2008 08:00 ET
|
Acura Pharmaceuticals, Inc.
BRISTOL, Tenn. and PALATINE, Ill., May 27, 2008 (PRIME NEWSWIRE) -- King Pharmaceuticals, Inc. (NYSE:KG) and Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that King has exercised its...
Acura Pharmaceuticals, Inc. Reports First Quarter 2008 Financial Results
April 30, 2008 16:05 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., April 30, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) reported net income of $7.4 million, or $0.15 per diluted share for the quarter ending March 31, 2008...
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX
April 24, 2008 08:15 ET
|
Acura Pharmaceuticals, Inc.
Top-Line Clinical Trial Results Expected by July 2008
NDA Submission Expected Before End of 2008
BRISTOL, Tenn. and PALATINE, Ill., April 24, 2008 (PRIME NEWSWIRE)...
Acura Pharmaceuticals, Inc. Names Robert B. Jones Chief Operating Officer
March 24, 2008 08:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., March 24, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) announced that Robert B. Jones has been named the Company's Senior Vice President and Chief Operating...